The effect of Xolair (omalizumab) on inhibiting leukotriene and cytokine (IL-4 and IL-13) release from blood basophils.

Trial Profile

The effect of Xolair (omalizumab) on inhibiting leukotriene and cytokine (IL-4 and IL-13) release from blood basophils.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Sep 2013

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Jul 2012 Planned end date changed from 1 Nov 2011 to 1 Nov 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top